Table 1.
Clinical data and estimation of interferon α by anti-rIFN α-2b antibodies in different RA patients
| Factor | RA patients (n = 60) | Control (n = 35) | |||
|---|---|---|---|---|---|
| Age, years | 66 ±5 | 50 ±3 | |||
| No. of men/no. of women | 3/57 | 2/33 | |||
| Disease duration (years) | 8.8 ±4.1 | – | |||
| CRP level, mg/dl | 4.1 ±1.8* | – | |||
| ESR | 42 ±3.9* | – | |||
| SF nuclear cells | 19110 ±3998* | – | |||
| SF protein (g/l) | 45.5 ±2.9* | – | |||
| WBC count, × 103/l | 9.1 ±3.5* | – | |||
| Rheumatoid factor positive (%) | 72 | – | |||
| Anti-CCP positive (%) | 68 | – | |||
| Methotrexate dose mg/week (mean) (n = 50) | 11.86 | – | |||
| Use of NSAIDs (%) | 61 | – | |||
| Infliximab (3 mg/kg) in combination with methotrexate (n) | 45 | – | |||
| Adalimumab 40 mg/every other week (n) | 16 | – | |||
| #Interferon α estimation in SF (n = 10) by: | |||||
| Anti-rIFN α-2b antibodies | 150.8 ±3.1 pg/ml$ | 145.3 ±5.1 pg/mla | |||
| Interferon α ELISA antibodies | 150.1 ±4.8 pg/ml | ||||
#
The amount of SF interferon α level was measured by ELISA and the values are presented as mean ±SD, an = 10
ESR – erythrocytes sedimentation rate, CRP – C reactive protein, SF – synovial fluid, WBC – white blood count
*
RA vs. normal subjects p < 0.05 (Student’s t-test)
$
Correlation coefficient r = 0.98 (p < 0.001)